Daratumumab does not bind to mouse CD38, and therefore in these in vivo experiments, an anti-mouse CD38 antibody (anti-mCD38) was used that exhibited characteristics of daratumumab, i.e., mediated in vitro ADCC and ADCP of mouse CD38-expressing tumor cells (Figure S5). This evidence concerns the gene CD38 and neoplasm.